American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and …

K Cusi, S Isaacs, D Barb, R Basu, S Caprio… - Endocrine Practice, 2022 - Elsevier
Objective To provide evidence-based recommendations regarding the diagnosis and
management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis …

Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD

N Tamaki, V Ajmera, R Loomba - Nature Reviews Endocrinology, 2022 - nature.com
Hepatic steatosis is a key histological feature of nonalcoholic fatty liver disease (NAFLD).
The non-invasive quantification of liver fat is now possible due to advances in imaging …

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis–2021 update

A Berzigotti, E Tsochatzis, J Boursier, L Castera… - Journal of …, 2021 - Elsevier
Non-invasive tests are increasingly being used to improve the diagnosis and
prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest …

[HTML][HTML] Non-alcoholic fatty liver disease: A patient guideline

SM Francque, G Marchesini, A Kautz, M Walmsley… - JHEP reports, 2021 - Elsevier
This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty
liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and …

Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A …

Y Cao, L Xiang, F Qi, Y Zhang, Y Chen, X Zhou - EClinicalMedicine, 2022 - thelancet.com
Background Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease,
and among the non-invasive tests, controlled attenuation parameter (CAP) and liver stiffness …

US attenuation for liver fat quantification: an AIUM-RSNA QIBA pulse-echo quantitative ultrasound initiative

G Ferraioli, V Kumar, A Ozturk, K Nam, CL de Korte… - Radiology, 2022 - pubs.rsna.org
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease
worldwide, with an estimated prevalence of up to 30% in the general population and higher …

Noninvasive assessment of liver fibrosis in NAFLD

AJ Sanyal, L Castera, VWS Wong - Clinical Gastroenterology and …, 2023 - Elsevier
Nonalcoholic fatty liver disease (NAFLD) has emerged as a leading cause of liver-related
morbidity and mortality worldwide, afflicting approximately a billion individuals. NAFLD is a …

Advances in the diagnosis and treatment of non-alcoholic fatty liver disease

X Yin, X Guo, Z Liu, J Wang - International Journal of Molecular Sciences, 2023 - mdpi.com
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease that
affects approximately one-quarter of the global adult population, posing a significant threat …

Quantification of liver fat content with ultrasound: a WFUMB position paper

G Ferraioli, A Berzigotti, RG Barr, BI Choi… - Ultrasound in medicine …, 2021 - Elsevier
New ultrasound methods that can be used to quantitatively assess liver fat content have
recently been developed. These quantitative ultrasound (QUS) methods are based on the …

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

ME Rinella, JV Lazarus, V Ratziu, SM Francque… - Hepatology, 2023 - journals.lww.com
The principal limitations of the terms NAFLD and NASH are the reliance on exclusionary
confounder terms and the use of potentially stigmatising language. This study set out to …